Caribou Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

CRBU$0.41-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Licensing and collaboration revenue (including $622 and $3,488 for three and nine months ended September 30, 2024, respectively, and $622 and $1,772 for three and nine months ended September 30, 2023, respectively, from related parties)	$2,024	$23,662	$7,917	$30,919
Operating expenses:
Research and development	30,421	28,584	99,689	80,796
General and administrative	9,841	9,711	35,969	28,740
Total operating expenses	40,262	38,295	135,658	109,536
Loss from operations	(38,238)	(14,633)	(127,741)	(78,617)
Other income:
Change in fair value of equity securities	(14)	(4)	(116)	3
Change in fair value of the MSKCC success payments liability	(164)	(139)	1,934	395
Other income, net	3,732	4,774	12,308	10,654
Total other income	3,554	4,631	14,126	11,052
Net loss	(34,684)	(10,002)	(113,615)	(67,565)
Other comprehensive income:
Net unrealized gain on available-for-sale marketable securities, net of tax	1,108	155	759	537
Net comprehensive loss	$(33,576)	$(9,847)	$(112,856)	$(67,028)
Net loss per share, basic and diluted	$(0.38)	$(0.12)	$(1.26)	$(0.98)
Weighted-average common shares outstanding, basic and diluted	90,455,900	83,783,992	90,034,799	68,878,921

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.